Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 2:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 178 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Eosinophilic Esophagitis Clear all
Completed Phase 3 Interventional

24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)

NCT05634746
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Drug · Procedure
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
59
States / cities
Dothan, Alabama • Mobile, Alabama • Scottsdale, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 11, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Dupilumab in Eosinophilic Gastritis

NCT03678545
View directory record Official record
Conditions
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Interventions
Dupilumab (blinded), Placebo (blinded)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Aurora, Colorado • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 11, 2026, 2:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing Anesthetic Techniques in Children Having Esophagogastroduodenoscopies

NCT02038894
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Intubated with Sevoflurane (IS), Intubated with Propofol (IP), Zofran - no intubation, Propofol
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 12 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 11, 2026, 2:41 PM EDT
Recruiting Phase 3 Interventional

A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis

NCT07112378
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Months to 6 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 11, 2026, 2:41 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Routine Screening for Eosinophilic Esophagitis in Patients Presenting With Dysphagia

NCT01028235
View directory record Official record
Conditions
Dysphagia
Interventions
Not listed
Lead sponsor
San Antonio Uniformed Services Health Education Consortium
Federal
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2009 · Synced Oct 11, 2026, 2:41 PM EDT
Completed Not applicable Interventional Results available

Use of Esophageal String Test to Understand Symptoms, Inflammation, and Function in Eosinophilic Esophagitis

NCT03305653
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Esophageal String Test (EST)
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
7 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 11, 2026, 2:41 PM EDT
Terminated No phase listed Observational

Systems Biology of Gastrointestinal and Related Diseases

NCT05579444
View directory record Official record
Conditions
Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp, Eosinophilic Esophagitis, GERD, Gastro Esophageal Reflux, Barrett Esophagus, Esophageal Cancer, Gastritis, Gastric Ulcer, Duodenal Ulcer, Intestinal Metaplasia, Gastric Cancer, Lymphocytic Colitis, Microscopic Colitis, Celiac Sprue, IBS, Irritable Bowel Syndrome, SIBO, NAFLD, Gallstone Disease
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 11, 2026, 2:41 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

NCT05831176
View directory record Official record
Conditions
Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
36
States / cities
Phoenix, Arizona • Apple Valley, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 11, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

NCT04753697
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
CC-93538, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
12 Years to 75 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
115
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 97 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 11, 2026, 2:41 PM EDT
Withdrawn No phase listed Observational

Eosinophilic Gastrointestinal Disorders Patient Registry

NCT01779154
View directory record Official record
Conditions
Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Enteritis, Eosinophilic Colitis
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Oct 11, 2026, 2:41 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

NCT04281108
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Drug · Procedure
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • Dothan, Alabama • Mobile, Alabama + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 11, 2026, 2:41 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Imaging of the Esophagus Using a SECM Capsule

NCT03546660
View directory record Official record
Conditions
Eosinophilic Esophagitis, Barrett Esophagus
Interventions
SECM capsule
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 11, 2026, 2:41 PM EDT
Terminated Not applicable Interventional

MRI to Assess Fibrosis in Eosinophilic Esophagitis Patients

NCT03446118
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
MRI to detect inflammation and fibrosis in subjects with EoE
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 11, 2026, 2:41 PM EDT
Completed No phase listed Observational

The Use of Fractionated Exhaled Nitric Oxide in the Diagnosis and Assessment of Disease Activity of Eosinophilic Esophagitis (Validation Phase)

NCT04941742
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
5 Years to 18 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 11, 2026, 2:41 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Morphological Markers of Gastroesophageal Reflux Disease (GERD)

NCT01921686
View directory record Official record
Conditions
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease
Interventions
Sample collection and Questionnaire
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
8 Years to 18 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 11, 2026, 2:41 PM EDT
Recruiting No phase listed Observational

Study of Gastric Motility in Eosinophilic Gastritis

NCT05229432
View directory record Official record
Conditions
Eosinophilic Gastritis, Gastroparesis, Gastric Motility Disorder
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 59 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Bethesda, Maryland • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 11, 2026, 2:41 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History and Genetics of Food Allergy and Related Conditions

NCT02504853
View directory record Official record
Conditions
Food Allergy, Loeys-Dietz Syndrome, Atopic Dermatitis, Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 99 Years
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 11, 2026, 2:41 PM EDT
Terminated Phase 1 Interventional

Sirolimus for Eosinophil-Associated Gastrointestinal Disorders

NCT01814059
View directory record Official record
Conditions
Eosinophilic Gastroenteritis, Eosinophilic Esophagitis
Interventions
sirolimus
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 11, 2026, 2:41 PM EDT
Recruiting No phase listed Observational

A Registry for the Food Allergy Community

NCT04653324
View directory record Official record
Conditions
Food Hypersensitivity, Anaphylaxis, Eosinophilic Esophagitis, Food Sensitivity, Food Intolerance, Food Allergy in Infants
Interventions
Not listed
Lead sponsor
Food Allergy Research & Education
Other
Eligibility
Not listed
Enrollment
23,000 participants
Timeline
2017 – 2027
U.S. locations
1
States / cities
McLean, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 11, 2026, 2:41 PM EDT
Recruiting No phase listed Observational

Changes in Esophageal Distensibility With Proton Pump Inhibitors in Patients With Esophageal Eosinophilia: A Pilot Study

NCT03312686
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
endoflip
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 11, 2026, 2:41 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Benralizumab for Eosinophilic Gastritis (BEGS)

NCT03473977
View directory record Official record
Conditions
Eosinophilic Gastritis or Gastroenteritis
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Oct 11, 2026, 2:41 PM EDT
Completed Phase 1Phase 2 Interventional

Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome

NCT00266565
View directory record Official record
Conditions
Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis, Churg-Strauss Syndrome, Eosinophilic Esophagitis
Interventions
Mepolizumab
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Oct 11, 2026, 2:41 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)

NCT05251909
View directory record Official record
Conditions
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 11, 2026, 2:41 PM EDT
Active, not recruiting No phase listed Observational

A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

NCT06693531
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Year and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
54
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 11, 2026, 2:41 PM EDT